Engineered Chinese shrub produces high levels of antimalarial compound

April 24, 2018, Cell Press
Growing A. annua plants. Credit: Ying Liu, Shanghai Xinhua News Agency

Artemisinin is a potent antimalarial compound produced naturally by the Chinese shrub Artemisia annua, commonly known as sweet wormwood. Currently,however, the low amount of artemisinin produced in the leaves of this plant does not meet the global demand. In a study published by April 24 in the journal Molecular Plant, researchers in China report a high-quality draft genome sequence of A. annua and their use of this information along with gene expression data to metabolically engineer plant lines that produce high levels of artemisinin. World Malaria Day is observed on April 25.

"Nearly half of the world's population is at risk of malaria," says senior study author Kexuan Tang of Shanghai Jiao Tong University. "Our strategy for the large-scale production of artemisinin will meet the increasing demand for this medicinal compound and help address this global health problem."

According to the World Health Organization, malaria affected approximately 216 million people in 91 countries in 2016 and caused an estimated 445,000 deaths worldwide that year alone. Plasmodium falciparum is the most prevalent malaria parasite on the African continent, and it is responsible for most malaria-related deaths globally. The best available treatment for malaria, particularly for cases caused by P. falciparum, is artemisinin-based combination therapy. In addition to its antimalarial activity, therapeutic effects of artemisinin have been reported for cancer, tuberculosis, and diabetes. However, the supply of artemisinin is limited because this medicinal compound typically makes up only 0.1%-1.0% of the dry weight of A. annua leaves.

To fully harness this compound's therapeutic potential, researchers have developed metabolic engineering strategies aimed at enhancing the expression of artemisinin biosynthetic pathway genes. These efforts failed to generate A. annua lines that produced high levels of artemisinin, though, primarily because they focused on modifying only upstream or downstream of the artemisinin biosynthetic pathway. A major hurdle for metabolic engineering strategies has been the lack of reference sequences and limited information about the genes involved in regulating artemisinin biosynthesis.

Kexuan Tang's research team and their A. annua plants. Credit: Ying Liu, Shanghai Xinhua News Agency

To address this problem, Tang and his collaborators generated a high-quality draft assembly of the 1.74 gigabase A. annua genome, which contains 63,226 protein-coding genes, one of the largest numbers among sequenced plant species. It took several years to complete the genome sequence due to its large size and high complexity. The study adds a wealth of information about Asteraceae, one of the largest families of plants consisting of more than 23,600 species of herbs, shrubs, and trees distributed throughout the world, including many with considerable medicinal, ornamental, and economic importance.

"A major impediment to the exploitation of the Asteraceae resources in basic and breeding sciences has been the absence of reference genome sequences; to date, only the sunflower and chrysanthemum genomes have been released," Tang says. "The A. annua genome and transcriptome data we provide here will be a valuable asset for fundamental biological research on plant evolution and other topics as well as applied breeding programs."

Of particular importance, the A. annua genome sequence provided new insights into the entire metabolic pathway involved in artemisinin biosynthesis. Analysis of the protein-coding genes and gene expression patterns revealed the sophisticated regulatory networks underlying artemisinin biosynthesis. Based on the genomic and transcriptomic data, the researchers identified novel genes involved in regulating artemisinin biosynthesis. By simultaneously increasing the activity of three —HMGR, FPS, and DBR2—spanning the entire artemisinin biosynthetic pathway, the researchers generated A. annua lines that produced high artemisinin levels—3.2% of the dry weight of the leaves.

Leveraging these findings, Tang and his team have sent artemisinin-rich seed samples to Madagascar, the African country that grows the most A. annua, for a field trial. They are also continuing to explore ways to enhance artemisinin production, with the goal of developing A. annua lines whose leaves contain 5% artemisinin.

"We hope our research can enhance the global supply of artemisinin and lower the price from the plant source," Tang says. "It is not expensive to generate high-level artemisinin lines. We have propagated hundreds of high artemisinin producer lines via cutting and selection, and scaled up the production of these . Hopefully our high transgenic lines will be grown at a massive scale next year."

Explore further: New plant engineering method could help fill demand for crucial malaria drug

More information: Molecular Plant, Shen, Q., Zhang, L., and Liao, Z., et al.: "The genome of Artemisia annua provides in 1 sight into the evolution of Asteraceae family and artemisinin biosynthesis" DOI: 10.1016/j.molp.2018.03.015

Related Stories

Transgenic plants against malaria

March 27, 2017

Scientists have discovered a gene that allows to double the production of artemisinin in the Artemisia annua plant.The artemisinin-based combination therapy (ACT) is the standard treatment for malaria worldwide, endorsed ...

First drug-resistant malaria parasite detected in Africa

February 22, 2017

For the first time in Africa, researchers said Wednesday they have detected a malaria parasite that is partially resistant to the top anti-malaria drug, artemisinin, raising concern about efforts to fight a disease that ...

Scientists in Germany improve malaria drug production

February 21, 2018

Scientists in Germany who developed a new way to make a key malaria drug several years ago said Wednesday they have come up with a technique to make the process even more efficient, which should increase global access and ...

Recommended for you

Floodplain forests under threat

March 19, 2019

A team from the Institute of Forest Sciences at the University of Freiburg shows that the extraction of ground water for industry and households is increasingly damaging floodplain forests in Europe given the increasing intensity ...

Scientists discover common blueprint for protein antibiotics

March 19, 2019

A discovery by researchers at the Los Angeles Biomedical Research Institute (LA BioMed) has uncovered a common blueprint for proteins that have antimicrobial properties. This finding opens the door to design and development ...

Nanoscale Lamb wave-driven motors in nonliquid environments

March 19, 2019

Light driven movement is challenging in nonliquid environments as micro-sized objects can experience strong dry adhesion to contact surfaces and resist movement. In a recent study, Jinsheng Lu and co-workers at the College ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Apr 24, 2018
Don't know which institution is funding this research but its amazing that the new strain is being so rapidly sent out into the world to heal people without someone with a profit motive getting in the way.
Hope someone like WHO funds more of their research.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.